Stefanie Urlinger

Dr. Stefanie Urlinger is Chief Scientific Officer at Cimeio Therapeutics, where they lead the Biology department. Stefanie has over 20 years of experience in antibody development and has worked at several companies in Germany, including OncoMab GmbH, MorphoSys AG, and iOmx Therapeutics AG. Dr. Urlinger obtained their PhD in Biology from the University of Heidelberg in 1999 and has been working in the field of antibody development ever since.

Stefanie Urlinger's educational career includes a postdoc at the University Erlangen-Nuernberg, a Doktor (Ph.D.) in Molecular Biology from the Max-Planck-Institute for Biochemistry in Martinsried, and a Dipl. Biol. in Biology from the University Regensburg. Stefanie has also been a visiting researcher in Molecular Biology at the University of Vienna.

Stefanie Urlinger reports to Thomas Fuchs, CEO. They work with Daniel Stark - Chief Manufacturing Officer, Thomas Winkler - Chief Medical Officer, and Lukas Jeker - Founder, SVP Gene Editing.